

on number of infections. In addition, contact tracing methods to limit the spread of infection will face considerable challenges.

This study has limitations. Selection bias is likely. The estimated prevalence may be biased due to nonresponse or that symptomatic persons may have been more likely to participate. Prevalence estimates could change with new information on the accuracy of test kits used. Also, the study was limited to 1 county. Serologic testing in other locations is warranted to track the progress of the epidemic.

Neeraj Sood, PhD
Paul Simon, MD
Peggy Ebner, BA
Daniel Eichner, PhD
Jeffrey Reynolds, MA
Eran Bendavid, MD
Jay Bhattacharya, MD, PhD

Author Affiliations: Schaeffer Center for Health Policy and Economics, Sol Price School of Public Policy, University of Southern California, Los Angeles (Sood); Los Angeles County Department of Public Health, Los Angeles, California (Simon); Keck School of Medicine, University of Southern California, Los Angeles (Ebner); Sports Medicine Research and Testing Laboratory, Salt Lake City, Utah (Eichner); LRW Group, Los Angeles, California (Reynolds); Stanford University School of Medicine, Palo Alto, California (Bendavid, Bhattacharya).

Corresponding Author: Neeraj Sood, PhD, University of Southern California, University Park Campus, Verna & Peter Dauterive Hall, 635 Downey Way, Los Angeles, CA 90089 (nsood@healthpolicy.usc.edu).

Accepted for Publication: May 1, 2020.

Published Online: May 18, 2020. doi:10.1001/jama.2020.8279

Author Contributions: Dr Sood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Sood, Simon, Ebner, Reynolds, Bendavid, Bhattacharya.

Drafting of the manuscript: Sood, Bendavid, Bhattacharya.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Sood, Simon, Reynolds, Bendavid, Bhattacharya.

Obtained funding: Sood, Eichner, Reynolds, Bendavid.

Administrative, technical, or material support: Sood, Simon, Ebner, Eichner, Reynolds, Bhattacharya.

Supervision: Sood, Simon, Ebner, Reynolds, Bhattacharya.

Conflict of Interest Disclosures: Dr Sood reported receiving funding from Jedel Foundation, USC Schwarzenegger Institute, USC Lusk Center, USC President's Office, Catherine Ahmed, Brent Bayless, Carole King, Daniel Eichner, Regina Nordhal, Tore Nordhal, and Gauri Jauhar during the conduct of the study; and reported serving as a scientific advisor to Payssurance and Virta Health; serving as an expert witness for the American Medical Association and Goldman, Ismail, Tomaselli, Brennan, and Baum; serving as an international expert for the China Development Research Foundation and the Pharmaceutical Research and Manufacturers of America; and receiving grants from the Agency for Healthcare Research and Quality, the National Institutes of Health, the National Institute for Health Care Management Foundation, Health Care Services Corporation, and the Patient-Centered Outcomes Research Institute outside the submitted work. Drs Bhattacharya and Bendavid reported receiving support from Jedel Foundation and the Stanford COVID-19 Seroprevalence Studies Fund during the conduct of the study. No other disclosures were reported.

Funding/Support: We received partial financial support for this project through the Stanford COVID-19 Seroprevalence Studies fund. We acknowledge funding from USC Schwarzenegger Institute, USC Lusk Center, USC President's Office, Jedel Foundation, LRW Group, Soap Box Sample, Foundation for Clean Competition, Partnership for Clean Competition, and several individual donors.

Role of the Funder/Sponsor: Funding organizations and donors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Jim Tedrow, BS, MT, The Compliance Resource Group; Thomas Kupiec, PhD, ARL Bio Pharma Inc; Manish J. Butte, MD, PhD, University of California, Los Angeles; Jason Brooks, LRW Group; and Thomas MaCurdy, Frank Wolak, and John P. A. Ioannidis, MD, DSc, Stanford University, for contributing to study design. We thank Ricardo Basurto-Davila, PhD, and Irene Vidyanti, PhD, Los Angeles County Chief Information Office, for contributing to study design and data collection. We thank Kevin de Leon, BA, and Conyers Davis, MA, Schwarzenegger Institute for State and Global Policy at the University of Southern California; and Carole King, MED, Sol Price School of Public Policy, University of Southern California, Los Angeles, for logistical support during data collection and securing funding. We thank John Walton Senterfitt and Alysia Kwon, ScM, Los Angeles County Department of Public Health, for IRB support. We thank Elinor Gaida, MBA, MPH, and Jacqueline Rosales, BS, LRW Group, for contributing to recruiting and data collection. We thank Janelle Cyprih, BS, Acacia Hori, BA, Alexandra Obrensky, BS, Katharine B. Stiers, BA, Silena Te, BA, Omar Toubat, BA, and other medical student volunteers from USC Keck School of Medicine for contributions to data collection. None of the individuals acknowledged received compensation from the study team.

1. Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. *Lancet Infect Dis*. 2020;S1473-3099(20)30246-2. Accessed April 9, 2020. Published online March 31, 2020. doi:10.1016/S1473-3099(20)30246-2

2. Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. *medRxiv*. Preprint posted online April 30, 2020. doi:10.1101/2020.04.14.20062463

3. Los Angeles County announces 18 new deaths related to 2019 novel coronavirus (COVID-19)—475 new cases of confirmed COVID-19 in Los Angeles County. News release. Los Angeles County Department of Public Health. April 10, 2020. Accessed April 26, 2020. <http://publichealth.lacounty.gov/phcommon/public/media/mediapubdetail.cfm?unit=media&ou=ph&prog=media&prid=2309>

Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults


Children account for less than 2% of identified cases of coronavirus disease 2019 (COVID-19).^{1,2} It is hypothesized that the lower risk among children is due to differential expression of angiotensin-converting enzyme 2 (ACE2),³ the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for host entry.⁴

We investigated ACE2 gene expression in the nasal epithelium of children and adults.

Methods | We conducted a retrospective examination of nasal epithelium from individuals aged 4 to 60 years encountered within the Mount Sinai Health System, New York, New York, during 2015-2018. Samples were collected from individuals with and without asthma for research on nasal biomarkers of asthma. The study was approved by the Mount Sinai institutional review board. Written informed consent was obtained from participants (or their parents for minors). Nasal epithelium was collected using a cytology brush that was immediately placed in RNA stabilization fluid and stored at -80 °C. RNA was isolated within 6 months. RNA samples were checked for quality and sequenced as a single batch in 2018. Sequence data processing included sequence alignment and normalization of gene expression counts across genes and samples.

Given the role of ACE2 in SARS-CoV-2 host entry,⁴ ACE2 gene expression was the focus of this study. Linear regression

Figure. Nasal Gene Expression of ACE2 in Different Age Groups



Data are means (data points) and 95% confidence intervals (error bars) for angiotensin-converting enzyme 2 (*ACE2*) gene expression in younger children (aged <10 years), older children (aged 10-17 years), young adults (aged 18-24 years), and adults (aged ≥25 years). Gene counts are shown as logarithmic (\log_2) counts per million. *P* values are from linear regression modeling in which *ACE2* gene expression in \log_2 counts per million was the dependent variable and age group was the independent variable.

models with and without adjustment for covariates (sex and asthma) were built with *ACE2* gene expression in \log_2 counts per million as the dependent variable and age group as the independent variable using R software, version 3.6.0 (R Foundation). Age was categorized into the following groups reflecting developmental life stages: younger children (aged <10 years), older children (aged 10-17 years), young adults (aged 18-24 years), and adults (aged ≥25 years). Two-sided tests and a significance threshold of $P \leq .05$ were used. Trend pattern was evaluated using polynomial orthogonal contrasts.

Results | The cohort of 305 individuals aged 4 to 60 years was balanced with regard to sex (48.9% male). Because the cohort had been recruited to study biomarkers of asthma, 49.8% had asthma.

We found age-dependent *ACE2* gene expression in nasal epithelium (Figure). *ACE2* gene expression was lowest (mean \log_2 counts per million, 2.40; 95% CI, 2.07-2.72) in younger children ($n = 45$) and increased with age, with mean \log_2 counts per million of 2.77 (95% CI, 2.64-2.90) for older children ($n = 185$), 3.02 (95% CI, 2.78-3.26) for young adults ($n = 46$), and 3.09 (95% CI, 2.83-3.35) for adults ($n = 29$).

Linear regression with *ACE2* gene expression as the dependent variable and age group as the independent variable showed that compared with younger children, *ACE2* gene expression was significantly higher in older children ($P = .01$), young adults ($P < .001$), and adults ($P = .001$) (Figure). As the distributions of sex and asthma varied among the age groups, a linear regression model adjusted for sex and asthma was built that also showed significant adjusted associations ($P \leq .05$) between *ACE2* expression and age group. Regression (β) coefficients for age groups from the unadjusted and adjusted models are shown in the Table. These regression coefficients

Table. β Coefficients for Age Group From Unadjusted and Adjusted Linear Regression Models^a

Age group, y ^b	β Coefficient (95% CI) ^c	
	Unadjusted model	Adjusted model ^d
10-17	0.37 (0.08-0.67)	0.30 (0.01-0.59)
18-24	0.63 (0.26-1.00)	0.49 (0.13-0.86)
≥25	0.69 (0.27-1.11)	0.52 (0.09-0.94)

^a Angiotensin-converting enzyme 2 gene expression in \log_2 counts per million was the dependent variable and age group was the independent variable.

^b Children younger than 10 years were the reference age group.

^c β Coefficients indicate the difference in *ACE2* gene expression (in \log_2 counts per million) between a given age group and the group of children younger than 10 years.

^d Adjusted for sex and asthma.

indicate the difference in *ACE2* expression (in \log_2 counts per million) between a given age group and the group of children younger than 10 years. Tests for trend using polynomial orthogonal contrasts indicated a significant linear trend for change in *ACE2* expression with advancing age group ($P \leq .05$).

Discussion | The results from this study show age-dependent expression of *ACE2* in nasal epithelium, the first point of contact for SARS-CoV-2 and the human body. Covariate-adjusted models showed that the positive association between *ACE2* gene expression and age was independent of sex and asthma. Lower *ACE2* expression in children relative to adults may help explain why COVID-19 is less prevalent in children.³ A limitation of this study is that the sample did not include individuals older than 60 years.

Few studies have examined the relationship between *ACE2* in the airway and age. A study of bronchoalveolar lavage fluid from 92 patients with acute respiratory distress syndrome reported no association between *ACE2* protein activity and age,⁵ but epithelial gene expression was not examined, and *ACE2* protein may be variably shed into bronchoalveolar lavage fluid. Furthermore, the lung and nasal environments are distinct, with known differences in gene expression.⁶ This study provides novel results on *ACE2* gene expression in nasal epithelium and its relationship with age.

Supinda Bunyavanich, MD, MPH

Anh Do, PhD

Alfin Vicencio, MD

Author Affiliations: Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (Bunyavanich, Vicencio); Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York (Do).

Corresponding Author: Supinda Bunyavanich, MD, MPH, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave #1498, New York, NY 10029 (supinda@post.harvard.edu).

Accepted for Publication: May 7, 2020.

Published Online: May 20, 2020. doi:10.1001/jama.2020.8707

Author Contributions: Dr Bunyavanich had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Bunyavanich, Do.

Drafting of the manuscript: Bunyavanich.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Bunyavanich, Do.

Obtained funding: Bunyavanich.

Administrative, technical, or material support: Bunyavanich.

Supervision: Bunyavanich, Vicencio.

Conflict of Interest Disclosures: Dr Vicencio reported being an investor in Filament Biosolutions. No other disclosures were reported.

Funding/Support: This study was funded by National Institutes of Health grant R01 AI118833.

Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Additional Contributions: We thank Robert Griffin, MD, PhD, Hospital for Special Surgery, and Yoojin Chun, MS, Icahn School of Medicine at Mount Sinai, for their assistance with manuscript preparation. Dr Griffin and Ms Chun did not receive compensation for their contributions.

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648

2. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(14):422-426. doi:10.15585/mmwr.mm6914e4

3. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. *Pediatrics*. 2020;145(4):e20200702. doi:10.1542/peds.2020-0702

4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

5. Schouten LR, van Kaam AH, Kohse F, et al; MARS Consortium. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. *Ann Intensive Care*. 2019;9(1):55. doi:10.1186/s13613-019-0529-4

6. Chun Y, Do A, Grishina G, et al. Integrative study of the upper and lower airway microbiome and transcriptome in asthma. *JCI Insight*. 2020;5(5):e133707. doi:10.1172/jci.insight.133707

Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Early Cancer Detection

Although screening for colorectal cancer reduces mortality, participation in screening is low. A randomized clinical trial that focused on sending specific reminders to general practitioners resulted in a modest but significant increase in



Supplemental content

patient participation after 1 year.¹ Data on the second co-primary outcome regarding cancer detection were not available at the time of publication² but are reported herein.

Methods | A cluster randomized clinical trial was conducted in France from July 14, 2015, to July 14, 2016, with medical practice as the unit of randomization. Details have been previously published.¹ The trial protocol (appears in [Supplement 1](#)) was approved by the Committee of Protection of Persons in Rennes, France, with a waiver of informed consent.

Briefly, patients eligible for screening (aged 50–74 years; asymptomatic; no family history of colorectal cancer; no personal history of colorectal cancer or adenoma >1 cm in diameter; and no colonoscopy within the past 5 years) are invited by mail to obtain a fecal immunochemical test (FIT) kit from their general practitioner. Patients who do not return a FIT

screening within 3 months are defined as nonadherent and receive a new invitation letter.

General practitioners in 801 practices and their nonadherent patients were included. Physicians were assigned to 1 of 3 groups: (1) the patient-specific reminders group, which received a list of nonadherent patients; (2) the generic reminders group, which received general information about regional screening adherence; and (3) the usual care group, which did not receive any reminders. The patient participation rates at 1 year were 24.8% in the patient-specific reminders group, 21.7% in the generic reminders group, and 20.6% in the usual care group, with the difference between the patient-specific reminders group and the other 2 groups reaching statistical significance.

The second co-primary outcome was the rate of colorectal cancer cases detected after 1 year, which was obtained from the regional cancer registry. This rate was calculated in each group as follows: the number of patients with colorectal cancer detected/the number of patients eligible for organized screening. The rates were compared among all 3 groups using a generalized linear mixed model with medical practices as the between-random effects. The same model was used to make pairwise comparisons.

The significance threshold was $P < .05$ and the testing was 2-sided. One of the goals of the study design was to avoid having missing data. The patients were analyzed according to their original allocation. All analyses were performed using R version 3.6.0 (R Foundation for Statistical Computing).

Results | Of 1482 randomized general practitioners, 1446 were included (496 in the patient-specific reminders group, 495 in the generic reminders group, and 455 in the usual care group). Of the 33 044 patients, 31 229 were included in the analysis. Characteristics of the general practitioners and patients have been published.¹

There were 102 patients (0.97% [95% CI, 0.79%–1.18%]) who underwent a colonoscopy in the patient-specific reminders group ($n = 10\,476$), 81 patients (0.76% [95% CI, 0.61%–0.95%]) in the generic reminders group ($n = 10\,606$), and 66 patients (0.65% [95% CI, 0.50%–0.83%]) in the usual care group ($n = 10\,147$) ([Table 1](#)).

Ten cases of colorectal cancer (0.10% [95% CI, 0.05%–0.18%]) were detected after 1 year in the patient-specific reminders group, 9 cases (0.08% [95% CI, 0.04%–0.16%]) in the generic reminders group, and 2 cases (0.02% [95% CI, 0.002%–0.07%]) in the usual care group (global effect of the randomization group on cancer detection, $P = .04$). The between-group differences were 0.010% (95% CI, –0.08% to 0.10%) for the patient-specific reminders group vs the generic reminders group ($P = .98$), 0.076% (95% CI, 0%–0.15%) for the patient-specific reminders group vs the usual care group ($P = .049$), and 0.065% (95% CI, –0.01% to 0.14%) for the generic reminders group vs the usual care group ($P = .08$) ([Table 2](#)).

Discussion | Providing general practitioners with a list of their nonadherent patients led to a modest increase in the number of cases of colorectal cancer detected after 1 year compared with usual care. There was no significant difference